The DOI matches its Crossref record; the references it cites are not checked yet.
Functional and Structural Recovery of the Retina after Gene Therapy in the RPE65 Null Mutation Dog
Abstract
PURPOSE: To assess the efficacy of AAV-mediated gene therapy to restore vision in a large number of RPE65(-/-) dogs and to determine whether systemic and local side effects are caused by the treatment. METHODS: Normal RPE65 dog cDNA was subcloned into an rAAV vector under control of a cytomegalovirus promoter, and an AAV.GFP control vector was also produced with the titers 2 x 10(12) particles/mL and 2 x 10(10) transducing U/mL, respectively. RPE65(-/-) dogs, aged 4 to 30 months were treated with subretinal injections of the AAV.RPE65 and control vectors, respectively, in each eye, and three 24- to 30-month-old normal control dogs with the latter. Baseline and postoperative systemic and ophthalmic examinations, blood screenings, vision testing, and electroretinography (ERG) were performed. Two RPE65(-/-) dogs were killed at 3 and 6 months after treatment for morphologic examination of the retinas. RESULTS: RPE65(-/-) dogs were practically blind from birth with nonrecordable or low-amplitude ERGs. Construct injections or sham surgeries were performed in 28 eyes; 11 were injected subretinally with the AAV.RPE65 construct. ERGs at 3 months after surgery showed that in the latter eyes, dark-adapted b-wave amplitudes recovered to an average of 28% of normal, and light adapted b-wave amplitudes to 32% of normal. ERG amplitudes were not reduced during a 6- to 9-month follow-up. No systemic side effects were observed, but uveitis developed in nine AAV.RPE65-treated eyes. No uveitis was observed in the eyes treated with the control vector. Immunocytochemistry showed expression of RPE65 in the retinal pigment epithelium (RPE) of AAV.RPE65-treated eyes. Fluorescence microscopy showed expression of green fluorescent protein (GFP) in the RPE and, to a lesser extent, in the neural retinas of AAV.GFP-treated eyes. Ultrastructurally, a reversal of RPE lipid droplet accumulation was observed at the AAV.RPE65 transgene injection site, but not at the site of injection of the control vector. CONCLUSIONS: In 10 of 11 treated RPE65(-/-) eyes, gene transfer resulted in development of vision, both subjectively apparent by loss of nystagmus, and objectively recorded by ERG. Structurally, there was reversal of lipid droplet accumulation in the RPE. Uveitis developed in 75% of the transgene-treated eyes, a complication possibly due to an immunopathogenic response to the RPE65 molecule.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An immune response to viruses and the generation of antibodies is a sign of a healthy functioning immune system, so the serum antibodies are not a cause for concern unless they cause inflammation.11,21,40,41”
From Systemic and local immune responses to intraocular AAV vector administration in non-human primates (2022) · cites this paper as [41]
In the citing paper
“Another canine study reported improved vision in 10 out of 11 RPE65-/animals that received AAV coding RPE65 by subretinal injections.However, 75% of the eyes that received AAV-RPE65 developed uveitis while the sham-injected and the AAV-GFP controls did not, implying that the uveitis was in response to the RPE65 gene/protein product.Additionally, there was a two-fold increase in anti-AAV antibodies”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [50]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 22 · Cited by 252
Metadata
- Authors
- Narfstro¨m, K., Katz, M. L., Bragadottir, R., Seeliger, M., Boulanger, A., Redmond, T. M., Caro, L., Lai, C.-M., & Rakoczy, P. E.
- Affiliations
- From the Vision Science Group, Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, and the
- University of Missouri (US)
- Department of Ophthalmology, Ulleval University Hospital, Oslo, Norway; the
- Universitätsklinikum Tübingen (DE)
- National Institutes of Health (US)
- The University of Western Australia (AU)
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2003-04-01
- Volume
- 44
- Issue
- 4
- Pages
- 1663
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2139489264
- Cited by
- 252
- References
- 22
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 6 · 2023: 2 · 2022: 6 · 2021: 6 · 2020: 5 · 2019: 7 · 2018: 7 · 2017: 9 · 2016: 6 · 2015: 10 · 2014: 17 · 2013: 9 · 2012: 11
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Funders
- University of Missouri
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- gene therapy, adeno-associated virus vectors, subretinal injection, retinal pigment epithelium, retinitis pigmentosa, electroretinogram, uveitis, visual recovery, canine model, cytomegalovirus promoter, retinal ultrastructure, immunocytochemistry, GFP expression, systemic side effects
- MeSH terms
- Dependovirus, Animals, Dark Adaptation, Dog Diseases, Dogs, Electroretinography, Eye Proteins, Female, Genetic Vectors, Indicators and Reagents, Luminescent Proteins, Male, Mutation, Night Blindness, Pigment Epithelium of Eye, Proteins, Retina, Retinal Degeneration, Uveitis, Vision Tests, Genetic Therapy, Gene Transfer Techniques, Green Fluorescent Proteins, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Functional and Structural Recovery of the Retina after Gene Therapy in the RPE65 Null Mutation Dog. https://app.cochat.ai/papers/10.1167/iovs.02-0595
- The paper
- Narfstro¨m, K., Katz, M. L., Bragadottir, R., Seeliger, M., Boulanger, A., Redmond, T. M., Caro, L., Lai, C.-M., & Rakoczy, P. E. (2003). Functional and Structural Recovery of the Retina after Gene Therapy in the RPE65 Null Mutation Dog. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.02-0595
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.